Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01, 2024 16:05 ET
|
Relay Therapeutics, Inc.
Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Relay Therapeutics Announces $30 Million Private Placement Financing
January 08, 2024 07:00 ET
|
Relay Therapeutics, Inc.
Relay Therapeutics Announces $30 Million Private Placement Financing
Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024 16:05 ET
|
Relay Therapeutics, Inc.
Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
Relay Therapeutics to Participate in Stifel 2023 Healthcare Conference
November 07, 2023 16:05 ET
|
Relay Therapeutics, Inc.
Relay Therapeutics to Participate in Stifel 2023 Healthcare Conference
Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights
November 02, 2023 16:05 ET
|
Relay Therapeutics, Inc.
Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights
Relay Therapeutics to Announce Third Quarter 2023 Financial Results and Corporate Highlights on November 2, 2023
October 26, 2023 16:05 ET
|
Relay Therapeutics, Inc.
Relay Therapeutics to Announce Third Quarter 2023 Financial Results and Corporate Highlights on November 2, 2023
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
October 12, 2023 16:05 ET
|
Relay Therapeutics, Inc.
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
September 18, 2023 16:05 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
August 08, 2023 16:02 ET
|
Relay Therapeutics, Inc.
Initiated dose expansion cohort for RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Updated RLY-2608 600mg BID + fulvestrant data: interim clinical...
Relay Therapeutics to Announce Second Quarter 2023 Financial Results and Corporate Highlights on August 8, 2023
August 01, 2023 16:05 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...